1/2상모집 중단 (진행 중)
Carfilzomib and Belatacept for Desensitization
연구 개요
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an acceptable donor is found for them or, they never receive a compatible donor, and die while on the kidney transplant waitlist. The purpose of this study is to find out whether two drugs, carfilzomib (Kyprolis®),and belatacept (Nulojix®), can make these kidney transplant candidates less sensitized, and make it easier and quicker to find a kidney donor for them.
- 스폰서
- 협력: BMS
- 적응증
- Highly Sensitized Prospective Kidney Transplant Recipients
- 중재
- carfilzomib, belatacept, Bone marrow aspiration
- 목표 등록
- 21명
- 시작일
- 2021-12-28
- 완료(예정)
- 2028-02-28
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.